Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: metabotropic glutamate receptor 2/3 antagonists - BrainCells/Taisho Pharmaceutical

Next Previous
Drug Profile

Research programme: metabotropic glutamate receptor 2/3 antagonists - BrainCells/Taisho Pharmaceutical

Alternative Names: BCI-1038; BCI-1208; BCI-1283; CNS programme - BrainCells/Taisho Pharmaceutical; Neurogenesis-promoting compounds

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer BrainCells
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - CNS disorders

Highest Development Phases

  • No development reported CNS disorders; Mood disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mood disorders in USA
  • 02 Mar 2012 A programme for metabotropic glutamate receptor 2/3 antagonists is available for licensing (\http://www.braincellsinc.com/\)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top